Bio News
Final approval follows successful PMDA on-site inspection at the end of 2025 Certification establishes supply foundation for ‘Immuncell-LC’ and ‘CD5 CAR-NK’
GC Cell has obtained manufacturing certification from Japan’s Ministry of Health, Labour and Welfare, establishing a foundation for supplying 2 anticancer drugs to Japan. The certification follows the company’s successful PMDA inspection at the end of 2025 and covers ‘Immuncell-LC,’ which is marketed in South Korea, and ‘CD5 CAR-NK,’ which is in a phase 1 clinical trial. The company plans to use Japan as a base to accelerate its entry into Asian markets.
BIOBOOK TEAM
biobookmedia@biobook.co.krBrazilian Health Regulatory Agency Approves Gazyva for a New Indication in Systemic Lupus Erythematosus
Belgium’s Amadcell acquires two Lakefront CAR T therapies for up to $230 million
OrbiMed Raises $3 Billion, Its Largest Asia Fund to Date
UK Researchers Identify New Mechanism of Antifungal Drug Resistance in Candida auris
AstraZeneca Signs $1.5 Billion AI Drug Target Discovery Deal With Insitro
Hyundai Pharmaceutical’s Third-Quarter Operating Profit Reaches KRW 5.937 Billion, Up 44% Year Over Year
